
Roya News
HealthJordan21 Nov 2026, 06:49
Experimental malaria vaccine achieves 87% efficacy in preventing infection
Machine translated | Original title: لقاح تجريبي للملاريا يحقق فعالية 87% في منع العدوى
The short version
A clinical trial showed that a new experimental malaria vaccine achieved 87% efficacy in preventing infection.
The full story
Recent clinical trial results revealed that an experimental malaria vaccine achieved high efficacy in preventing infection. The findings were presented during the annual meeting of the American Society of Tropical Medicine and Hygiene held in Washington. The vaccine, known as PfSPZ-LARC2, utilizes a genetically attenuated live parasite designed to stimulate immunity without allowing the pathogen to complete its growth in the liver.
During controlled trials, participants were deliberately exposed to the disease several weeks after receiving their final doses. All individuals who received a placebo contracted the infection, whereas only two out of fifteen participants in the vaccinated group became infected, resulting in thirteen protected individuals. All infected participants received prompt and proper treatment, while the vaccine itself proved to be safe and well-tolerated.
Significantly, the vaccine developed from a West African strain was tested against a different strain originating from Brazil, raising hopes for broad protection against diverse variants. Researchers are continuing to advance the development of the vaccine in preparation for further upcoming studies, aiming to address a disease that claims over six hundred thousand lives globally each year.
Source: Roya News
Read the full story at the sourceAsk Fahim about this story
Fahim answers from this story and, when it is not there, searches the web and keeps that part separate. No opinions.
Automated answers from the story text; they can be wrong. Check the source.




Comments
Comments are checked automatically. No abuse, links or phone numbers.